Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.452 | 1 | 1 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Echinococcus multilocularis | thymidylate synthase | 0.0671 | 0.0115 | 0.0115 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.452 | 1 | 1 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Chlamydia trachomatis | dihydrofolate reductase | 0.452 | 1 | 0.5 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.452 | 1 | 1 |
Schistosoma mansoni | dihydrofolate reductase | 0.452 | 1 | 1 |
Echinococcus multilocularis | dihydrofolate reductase | 0.452 | 1 | 1 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.452 | 1 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Brugia malayi | Dihydrofolate reductase | 0.452 | 1 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.2568 | 0.4987 | 0.5 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Echinococcus granulosus | thymidylate synthase | 0.0671 | 0.0115 | 0.0115 |
Echinococcus granulosus | dihydrofolate reductase | 0.452 | 1 | 1 |
Onchocerca volvulus | 0.0671 | 0.0115 | 0.5 | |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.2568 | 0.4987 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 115 nM | Tested in vitro for GH-releasing potency against rat pituitary cells. | ChEMBL. | 9733495 |
ED50 (functional) | > 266 nM | Tested in vivo for GH-releasing potency against anesthetized male rats | ChEMBL. | 9733495 |
Emax (functional) | = 85 % | Tested in vitro for GH-releasing potency against rat pituitary cells. | ChEMBL. | 9733495 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.